Phase I data presented at the American Heart Association (AHA) 2025 meeting and published in The New England Journal of Medicine ( NEJM ) showed deep, dose-dependent reductions in ANGPTL3 (up to 89%) with corresponding decreases in triglycerides and LDL cholesterol, including in patients already on standard lipid-lowering therapy
Understanding these potential connections and implementing practical preventive strategies can help patients manage symptoms effectively whilst continuing beneficial diabetes or weight management therapy under appropriate medical supervision
Cancer 2014;120(12):1890-1897
Fabi, & Dr
Sim, R., Sez-Lpez, C., Barbosa-Desongles, A., Hernndez, C
It may also help with other things, such as fighting infection, managing certain neurological conditions, reducing the chance of heart disease, and more